These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 39028343)

  • 1. Gut microbiota and metabolites of cirrhotic portal hypertension: a novel target on the therapeutic regulation.
    Hao Y; Hao Z; Zeng X; Lin Y
    J Gastroenterol; 2024 Sep; 59(9):788-797. PubMed ID: 39028343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
    Arab JP; Martin-Mateos RM; Shah VH
    Hepatol Int; 2018 Feb; 12(Suppl 1):24-33. PubMed ID: 28550391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis.
    Sorribas M; Jakob MO; Yilmaz B; Li H; Stutz D; Noser Y; de Gottardi A; Moghadamrad S; Hassan M; Albillos A; Francés R; Juanola O; Spadoni I; Rescigno M; Wiest R
    J Hepatol; 2019 Dec; 71(6):1126-1140. PubMed ID: 31295531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The gut-liver axis in liver disease: Pathophysiological basis for therapy.
    Albillos A; de Gottardi A; Rescigno M
    J Hepatol; 2020 Mar; 72(3):558-577. PubMed ID: 31622696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gut-liver axis signaling in portal hypertension.
    Simbrunner B; Mandorfer M; Trauner M; Reiberger T
    World J Gastroenterol; 2019 Oct; 25(39):5897-5917. PubMed ID: 31660028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microbiota transplants from feces or gut content attenuated portal hypertension and portosystemic collaterals in cirrhotic rats.
    Huang HC; Tsai MH; Chang CC; Pun CK; Huang YH; Hou MC; Lee FY; Hsu SJ
    Clin Sci (Lond); 2021 Dec; 135(24):2709-2728. PubMed ID: 34870313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential mechanisms linking gut microbiota and portal hypertension.
    Baffy G
    Liver Int; 2019 Apr; 39(4):598-609. PubMed ID: 30312513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.
    Schwabl P; Hambruch E; Seeland BA; Hayden H; Wagner M; Garnys L; Strobel B; Schubert TL; Riedl F; Mitteregger D; Burnet M; Starlinger P; Oberhuber G; Deuschle U; Rohr-Udilova N; Podesser BK; Peck-Radosavljevic M; Reiberger T; Kremoser C; Trauner M
    J Hepatol; 2017 Apr; 66(4):724-733. PubMed ID: 27993716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gut-Liver Axis Dysregulation in Portal Hypertension: Emerging Frontiers.
    Lombardi M; Troisi J; Motta BM; Torre P; Masarone M; Persico M
    Nutrients; 2024 Apr; 16(7):. PubMed ID: 38613058
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gut microbiota-related complications in cirrhosis.
    Gómez-Hurtado I; Such J; Sanz Y; Francés R
    World J Gastroenterol; 2014 Nov; 20(42):15624-31. PubMed ID: 25400446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating microbiome in patients with portal hypertension.
    Gedgaudas R; Bajaj JS; Skieceviciene J; Varkalaite G; Jurkeviciute G; Gelman S; Valantiene I; Zykus R; Pranculis A; Bang C; Franke A; Schramm C; Kupcinskas J
    Gut Microbes; 2022; 14(1):2029674. PubMed ID: 35130114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microbial Profiles of Cirrhosis in the Human Small Intestine.
    Dong TS; Jacobs JP; Hussain SK
    Curr Gastroenterol Rep; 2019 Aug; 21(10):50. PubMed ID: 31444636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bile acid is a significant host factor shaping the gut microbiome of diet-induced obese mice.
    Zheng X; Huang F; Zhao A; Lei S; Zhang Y; Xie G; Chen T; Qu C; Rajani C; Dong B; Li D; Jia W
    BMC Biol; 2017 Dec; 15(1):120. PubMed ID: 29241453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploratory Research on the Relationship between Human Gut Microbiota and Portal Hypertension.
    Yokoyama K; Tsuchiya N; Yamauchi R; Miyayama T; Uchida Y; Shibata K; Fukuda H; Umeda K; Takata K; Tanaka T; Inomata S; Morihara D; Takeyama Y; Shakado S; Sakisaka S; Hirai F
    Intern Med; 2020; 59(17):2089-2094. PubMed ID: 32879200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gut microbiota, cirrhosis, and alcohol regulate bile acid metabolism in the gut.
    Ridlon JM; Kang DJ; Hylemon PB; Bajaj JS
    Dig Dis; 2015; 33(3):338-45. PubMed ID: 26045267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Use of Rifaximin in Patients With Cirrhosis.
    Caraceni P; Vargas V; Solà E; Alessandria C; de Wit K; Trebicka J; Angeli P; Mookerjee RP; Durand F; Pose E; Krag A; Bajaj JS; Beuers U; Ginès P;
    Hepatology; 2021 Sep; 74(3):1660-1673. PubMed ID: 33421158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved hemodynamic and liver function in portal hypertensive cirrhotic rats after administration of B. pseudocatenulatum CECT 7765.
    Gómez-Hurtado I; Zapater P; Portune K; Juanola O; Fernández-Iglesias A; González-Navajas JM; Gracia-Sancho J; Sanz Y; Francés R
    Eur J Nutr; 2019 Jun; 58(4):1647-1658. PubMed ID: 29748815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infection as a Trigger for Portal Hypertension.
    Steib CJ; Schewe J; Gerbes AL
    Dig Dis; 2015; 33(4):570-6. PubMed ID: 26159275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The gut microbiota-bile acid axis in cholestatic liver disease.
    Sun D; Xie C; Zhao Y; Liao J; Li S; Zhang Y; Wang D; Hua K; Gu Y; Du J; Huang G; Huang J
    Mol Med; 2024 Jul; 30(1):104. PubMed ID: 39030473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Digestive dynamics: Unveiling interplay between the gut microbiota and the liver in macronutrient metabolism and hepatic metabolic health.
    Kandalgaonkar MR; Kumar V; Vijay-Kumar M
    Physiol Rep; 2024 Jun; 12(12):e16114. PubMed ID: 38886098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.